NasdaqHealth CarePharmaceutical PreparationsSAN DIEGO, CA

Gyre Therapeutics, Inc. GYRE

Ask your AI

Estimated market cap $497.03M115.32M shares, shares as of Nov 1, 2026CIK 1124105

Insider trades, 12 mo

0 buys · 18 sells

$952.9K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

7.2% of shares · 15 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Gyre Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 6, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Gyre Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

18 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 18, 2026. Insiders have two business days to file.

Recent insider trades

Weiguo Ye Chief Operating Officer	Jun 18 Form 4 ↗	Sale	−$19.1K 3,000 sh @ $6.35	-32.1%
Weiguo Ye Chief Operating Officer	Jun 10 Form 4 ↗	Sale	−$31.2K 5,000 sh @ $6.24	-31.6%
Weiguo Ye Chief Operating Officer	Jun 9 Form 4 ↗	Sale	−$18.4K 3,000 sh @ $6.15	-32.0%
Weiguo Ye Chief Operating Officer	Jun 11 Form 4 ↗	Sale	−$17.3K 2,800 sh @ $6.17	-31.1%
Weiguo Ye Chief Operating Officer	Jun 10 Form 4 ↗	Sale	−$39.9K 6,418 sh @ $6.21	-31.6%

All GYRE insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

8.34M shares

37 funds report GYRE. Values checked against market prices.

Funds own 7.8% of shares (Q2 2026)

59 funds hold the stock.

Q3 2026: 7.2% · 5,560 of ~8,900 funds reported so far

Q2 20253.5%
Q3 20253.2%
Q4 20253.4%
Q1 20263.5%
Q2 20267.8%
Q3 2026 (so far)7.2%

Q3 2026. 3 new, 15 added to, 13 trimmed, 26 exited since Q2 2026.

Top 13F holders
#
1	HSG Holding Ltd 13F ↗	3.75M	$27.5M	unchanged
2	Vanguard Capital Management LLC 13F ↗	1.47M	$10.8M	+67.3%
3	BlackRock, Inc. 13F ↗	1.18M	$8.6M	+18.2%
4	Geode Capital Management, LLC 13F ↗	681,326	$5.0M	+27.8%
5	State Street Corp 13F ↗	246,872	$1.8M	+0.6%
6	Vanguard Fiduciary Trust Co 13F ↗	243,373	$1.8M	+61.1%
7	UBS Group AG 13F ↗	203,880	$1.5M	+986.6%
8	SBI Securities Co., Ltd. 13F ↗	169,717	$1.2M	+1.8%
9	Vanguard Portfolio Management LLC 13F ↗	107,166	$785.5K	-13.5%
10	Bank of New York Mellon Corp 13F ↗	56,241	$412.2K	-10.4%

Download CSV Every fund that holds GYRE, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Gyre Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Gyre Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2023	15	—	607,067	$15.6M
Q1 2024	21	+6	848,284	$14.8M
Q2 2024	30	+9	1.26M	$15.0M
Q3 2024	37	+7	1.61M	$20.2M
Q4 2024	40	+3	1.79M	$21.6M
Q1 2025	45	+5	2.61M	$20.1M
Q2 2025	48	+3	3.42M	$25.1M
Q3 2025	48	0	3.10M	$23.1M
Q4 2025	44	-4	3.34M	$23.6M
Q1 2026	56	+12	3.41M	$23.8M
Q2 2026	60	+4	8.67M	$57.1M
Q3 2026	37	-23	8.34M	$61.1M

Each point is a quarter-end, from Q4 2023 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (403783103). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2023) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes3 in 12 mo 8-K events4 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 1 in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: GYRE THERAPEUTICS, INC.
Address: 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA 92130
Phone: (858) 284-0115
Fiscal year ends: Dec 31
Filer category: Accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: GYRE (Nasdaq)
Former names: CATALYST BIOSCIENCES, INC. (until 2023); TARGACEPT INC (until 2015)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$4.31+$0.01 (+0.23%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $4.01 · High $7.09Nov 13, 2026

Aug 13, 2026Low $4.01 · High $7.55Nov 13, 2026

Nov 13, 2025Low $4.01 · High $8.76Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.